SCHEMBL10178248

SCHEMBL10178248

CNCc1ccc(-c2cc(-c3nc(Br)cnc3N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)on2)c(F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 14/20 0.39
ATM Q13315 4/20 0.39
PRKDC P78527 3/20 0.39
JAK2 O60674 1/20 0.38
ABL1 P00519 1/20 0.38
KIT P10721 1/20 0.38
SERPINA2 P20848 1/20 0.38
PIK3R1 P27986 1/20 0.38
FLT4 P35916 1/20 0.38
FLT3 P36888 1/20 0.38
PIK3CA P42336 1/20 0.38
MTOR P42345 1/20 0.38
SYK P43405 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
MAP3K9 P80192 1/20 0.38
KCNH2 Q12809 1/20 0.38
MERTK Q12866 1/20 0.38
DYRK2 Q92630 1/20 0.38
AAK1 Q2M2I8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL506015 0.89 PPARA (0.31) ATRHDAC1HDAC6
SCHEMBL29458740 0.89 PPARA (0.31) ATRHDAC1HDAC6
SCHEMBL2486777 0.88 PPARA (0.32)
SCHEMBL30275211 0.85 GPR119 (0.43)
SCHEMBL30275081 0.83 CXCR1 (0.35)
SCHEMBL31349705 0.83 CXCR1 (0.35)
SCHEMBL506684 0.81 ATR (0.37) ATRATMPRKDCJAK2ABL1
SCHEMBL30275257 0.81 ATR (0.37) ATRATMPRKDCJAK2ABL1
SCHEMBL31349713 0.80 ATR (0.39) ATRATMPRKDCJAK2ABL1
SCHEMBL506852 0.80 ATR (0.53) ATRATMPRKDCJAK2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9630956-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-04-25 US disclosed
US-9630956-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-04-25 US disclosed
US-20120027874-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-02 US disclosed
US-20120027874-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-02 US disclosed
WO-2011143426-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120027874-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 ATR 1/4885ATM 32/4885PRKDC 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.